Of note, ivacaftor (formerly VX-770, marketed as Kalydeco®), the first CFTR-modulating drug to receive U.S. Food and Drug Administration (FDA) approval in 2012, drastically changed the treatment of nearly 10% of CF patients. The gene discussed is CFTR; the disease is cystic fibrosis.